Navigation Links
Novartis Gleevec Found Effective in Treating Gastro-intestinal Tumors

The US-based National Cancer Institute (NCI) has commended Novartis' anti-cancer tablet, Gleevec, as an// effective therapy for patients suffering from GISTs, metastatic gastro-intestinal tumors.

These tumours do have a rather complicated name. They are found in the digestive system - the gastrointestinal tract. They develop from cells of connective tissues that control the movements of the gut.

The tissues that support body organs are called the 'stroma', so that's where the stromal bit comes from. Cancers of connective tissues are 'sarcomas'. So the full name is gastrointestinal stromal sarcoma.

Some GISTS are benign (not cancerous) but they can become cancerous if not treated. Generally speaking, the larger the GIST, the more likely it is to be cancerous. It is estimated that approximately 5,000 to 6,000 new patients are diagnosed with GIST each year in the United States.

The NCI said that preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary GIST, showed that patients who received imatinib mesylate (Gleevec) after complete removal of their tumor were significantly less likely to have a recurrence of their cancer compared to those who did not receive imatinib. There was no recurrence of cancer in approximately 97 per cent of patients given Gleevec for a year after surgery to remove tumors, compared to approximately 83 per cent of those who underwent surgery but received a placebo.

The Novartis has lately come under a lot of fire over its continuing battle in Indian courts to patent Gleevec. In such a backdrop, the NCI's preliminary findings should be welcome for it.

Novartis supplied Gleevec for use in the study involving 600 patients, and also provided partial funding under a cooperative research and development agreement with NCI to support the clinical development of Gleevec.

"These results have major implica tions for patients with primary GIST," noted the principal investigator of the study, Ronald DeMatteo, Memorial Sloan-Kettering Cancer Center at New York.

"Conventional chemotherapy agents have been notoriously ineffective in GIST. This study for the first time demonstrated that targeted molecular therapy reduces the rate of recurrence after complete removal of a primary GIST."

Diane Young, Head of Global Medical Affairs at Novartis Oncology, said, "With these new data, we see that Gleevec may help patients with early GIST. We will now work with the investigators on a submission to gain regulatory approval for Gleevec as adjuvant treatment for GIST."

Adjuvant therapy is treatment given in addition to the primary therapy to kill any cancer cells that may have spread, even if the spread cannot be detected by radiologic or laboratory tests.

Related medicine news :

1. Novartis files application with FDA for Zometa
2. Canine Painkiller unveiled by Novartis
3. Glivec the hot cancer drug from Novartis
4. Zometa [Novartis Drug] For Treatment Of Paget’s Diseas
5. Novartis MS Drug Shows Promising Results
6. Bird-flu Vaccine Adjuvant Contract Goes to Novartis
7. Drop Patent Petition, Activists Ask Novartis
8. E.U. Panel Backs Novartis Mock-up Pandemic Flu Vaccine
9. Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board
10. Novartis Drug Diovan Shows Superior Benefits
11. Gleevec gets hopeful results
Post Your Comments:

(Date:11/25/2015)... ... 25, 2015 , ... According to an article published November 10th ... widely heralded as a breakthrough for performing hernia repairs. The article explains that the ... is that it can greatly reduce the pain that a patient might otherwise experience ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug ... a new cutting edge recovery program that has been 50 years in the making. ... individuals with the purpose to free addicts from the symptoms and negative behaviors of ...
(Date:11/25/2015)... ... , ... On November 23rd 2015 Cozy Products, a division of ... Cozy Products explains what this means for business moving forward. , The Tri Lite ... business model: to sell personal heaters that reduce energy consumption, are economical and keep ...
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new ... systems. The new app features a more intuitive SleepScore™ that rates sleep quality on ... slept. The SleepScore is created by a proprietary algorithm. Beddit analyzes the data to ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, ... from Bronx, N.Y. “I thought there had to be a convenient and comfortable way ... , The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 AAIPharma Services ... investment of at least $15.8  Million to expand ... Wilmington, NC . The expansion will provide ... meet the growing demands of the pharmaceutical and ... site expansion will provide up to 40,000 square ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
(Date:11/25/2015)... 25, 2015 USP 800 applies to ... (e.g. pharmacists, pharmacy technicians, nurses, physicians, physician assistants, ... chapter also covers all entities which store, prepare, ... other healthcare institutions, patient treatment clinics, physicians, practice ... --> What is the purpose ...
Breaking Medicine Technology: